-
Study aim
-
the effectiveness of pentoxifylline compared to dexamethasone in diabetic patients with covid-19
-
Design
-
The double-blind, randomized, controlled trial study conducted on 50 diabetic patients with COVID-19. Randomization will be performed using a table of random numbers. Patients will be randomly assigned to either the pentoxifylline/dexamethasone group or the dexamethasone-only group after obtaining written informed consent.
-
Settings and conduct
-
Patients diagnosed with COVID-19 who are hospitalized in two educational hospitals in Yazd (Shahid Rahnamoon and Shahid Sadoughi Hospitals) will be included in the study, provided that they have diabetes.
-
Participants/Inclusion and exclusion criteria
-
Patients aged 18 to 70 years with a diagnosis of COVID-19 within the last 24 to 48 hours, and candidates for hospitalization (o2sat <93%, RR> 24, or Pao2/Fio2 <300) are enrolled in the study. Patients undergoing treatment with Kaletra, patients with hemodynamic instability, drug intolerance, a history of Crohn's, chronic diarrhea, neuromuscular diseases, GFR less than 30 ml/min, a history of cirrhosis, hepatitis, or severe liver disease, patients with cancer, and pregnant or lactating patients will be excluded from the study.
-
Intervention groups
-
patients are treated with a dosage of 400 mg three times a day, along with intravenous administration of dexamethasone at a dose of 4 mg every 12 hours. In the control group, patients only receive intravenous dexamethasone at a dose of 4 mg every 12 hours. Treatment continues for seven days.
-
Main outcome variables
-
The improvement of the general condition of the patients, the levels of inflammatory markers and the level of involvement in the HRCT before the admission of the patients, any possible drug complications, as well as the need for hospitalization in the intensive care unit and the need for intubation, as well as the mortality rate will be recorded.